ONESOURCE1,548.10

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,744 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.270.800.72
Interest Burden (Pretax/EBIT) ×-0.35-3.66-1.20
EBIT Margin %13.331.773.63
Asset Turnover ×0.190.170.17
Financial Leverage (Assets/Equity) ×1.281.411.41
ROE (5-step product) %-0.30-1.24-0.75
ROE (reported, avg-equity basis) %-0.31-1.27-1.27
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.